Mobile

An open label study to Evaluate Efficacy, Safety and Mucosal Healing of early versus late use of vedolizumab in ulcerative colitis: the LOVE-UC study (LOw countries VEdolizumab in UC study) LOVE-UC ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-005443-40

An open label study to Evaluate Efficacy, Safety and Mucosal Healing of early versus late use of vedolizumab in ulcerative colitis: the LOVE-UC study (LOw countries VEdolizumab in UC study) LOVE-UC Een fase 4, open-label studie ter evaluatie van de effect, veiligheid en genezing van het darmslijmvlies bij vedolizumab gebruik in een vroeg versus een later stadium van colitis ulcerosa: de LOVE-UC studie (LOw countries VEdolizumab in UC study)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this prospective open label study is to assess the ability of vedolizumab to promote clinical, endoscopic and histological remission in patients with active UC in an 'early' and a 'late' disease population after 54 weeks of treatment.

Critère d'inclusion

  • Ulcerative colitis,Colitis Ulcerosa

Liens